Avotres Inc. is a biotechnology company that leverages revolutionary drug targets to develop and commercialize transformational therapies in autoimmune diseases, cancers and transplantation. We consider it our mission to tackle the root cause of these diseases and aim to reach the ultimate goal of relieving patients from the disease burden.
Our lead asset, AVT001, a cell therapy, is developed to address the common root cause of autoimmune diseases, i.e. loss of self-tolerance. By targeting the novel upstream CD8+ regulatory T cell (CD8+ Treg) mediated pathway, AVT001 has the potential to restore self-tolerance in autoimmune disease patients, thus creating a solid platform to treat a large number of autoimmune diseases efficiently as a disease modifying agent, and even bring a potential cure to some of those patients.
At present, AVT001 is in an ongoing double blind, placebo controlled, phase I/II combined clinical trial in the United States for the treatment of Type 1 Diabetes (T1D). T1D is a complex, chronic, T cell-mediated autoimmune disease in which the insulin producing pancreatic β cells are destroyed by one’s own immune system. We hope our AVT001 can stop the self-attack on pancreatic β cells in T1D patients, leading to the prevention, relief and potential cure of T1D.
In addition to T1D, AVT001 has demonstrated in our preclinical studies its potential for disease modification in many other autoimmune diseases, and for reducing chronic rejection of allografts in organ transplantation without the use of any systemic immuno-suppressant(s).
We are also developing a monoclonal antibody (mAb), AVT002, as a potential cancer therapy directed at a novel immuno-oncology target. AVT002 has so far demonstrated significant efficacy in a mouse melanoma model.
Related to our novel CD8+ Treg peripheral self-tolerance pathway, as part of our portfolio, AVT-Dx 001 is a potential clinical diagnostic test for precise and potentially early diagnosis of autoimmune diseases.
With its solid multi-asset platform, Avotres is steadily advancing its pipeline to address high unmet medical needs and eventually provide patients with revolutionary medical solutions for their diseases, including potential cures.